Opdivo Keeps Melanoma from Recurring Longer Than Yervoy, Phase 3 Clinical Trial Shows
News
It took longer for advanced melanoma to recur in patients treated with Bristol-Myers Squibb’s Opdivo (nivolumab) than in patients who received Yervoy, according to a Phase 3 clinical trial. The ... Read more